New drug combo as first treatment for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign the consent form.
- You have advanced or stage IV non-small cell lung cancer (NSCLC) that cannot be removed with surgery or treated with radiation.
- Your PD-L1 test result is 1% or higher.
- You have not received chemotherapy, targeted therapy, or immunotherapy for your lung cancer before.
- Your cancer does not have certain gene changes (EGFR, ALK, ROS1) that are common in adenocarcinoma.
- You are generally healthy enough to be up and about (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mix of high and low dose radiation along with chemotherapy and immunotherapy for people with locally advanced non-small cell lung cancer. It aims to see if this combination can improve treatment outcomes.
This trial tests a combination of the immunotherapy drug tislelizumab, standard chemotherapy, and an antihistamine (diphenhydramine) as a first treatment for advanced non-small cell lung cancer. The antihistamine may help reduce side effects or improve the immune response.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.